In This Article

The short answer: LDL cholesterol (LDL-C) measures the mass of cholesterol carried inside LDL particles. LDL particle number (LDL-P) counts the particles themselves. In the Multi-Ethnic Study of Atherosclerosis, when a person's LDL-C and LDL-P disagreed, LDL-P predicted future cardiovascular events (hazard ratio 1.45) while LDL-C alone did not (hazard ratio 1.07, not statistically significant). That gap exists because cholesterol per particle varies with particle size, so two people with the same LDL-C can carry very different numbers of atherogenic particles. LDL-P and ApoB, a related particle count, are most useful as a check on LDL-C rather than a replacement for it, especially for anyone with elevated triglycerides, insulin resistance, or a low-carbohydrate diet.

Read key takeaways →

What LDL-P actually measures

A standard lipid panel reports LDL cholesterol, the total mass of cholesterol carried by all circulating LDL particles combined. LDL-P, or LDL particle number, measures something different: the actual count of those particles, regardless of how much cholesterol each one is carrying. The distinction sounds small, but it changes how the same blood draw should be interpreted.

LDL particles are not uniform. Some are large and cholesterol-rich, others are small and dense with comparatively little cholesterol packed inside. LDL-P is typically measured by nuclear magnetic resonance (NMR) spectroscopy, a method described by Elias Jeyarajah, William Cromwell, and James Otvos in a 2006 methods paper in Clinics in Laboratory Medicine. Each LDL particle size class produces a distinct NMR signal from its lipid methyl groups, and the amplitude of that signal is proportional to the number of particles present, which lets a lab count particles directly rather than inferring them from cholesterol mass.

LDL-C

Cholesterol mass

The total cholesterol cargo carried inside all LDL particles. Standard on every routine lipid panel.

LDL-P

LDL particle count

Counted directly by NMR spectroscopy. Reflects how many LDL particles are actually circulating, not their cholesterol content.

ApoB

Total particle count

One ApoB protein sits on every LDL, VLDL, and IDL particle, so ApoB counts the broader atherogenic particle pool, not LDL alone.

ApoB and LDL-P usually track closely because LDL particles make up the large majority of the ApoB-carrying pool in most people. The lipid panel guide covers ApoB and Lp(a) in the context of a full panel; this article focuses specifically on what LDL-P adds and, more importantly, on the situations where it and LDL-C stop agreeing with each other.

Why LDL-C and LDL-P disagree

Because LDL-C measures mass and LDL-P measures count, the two numbers only move in lockstep if the average amount of cholesterol per particle stays constant. It does not. Small, dense LDL particles carry less cholesterol per particle than large, buoyant ones, so a person whose LDL population has shifted toward smaller particles needs more particles in circulation to carry the same total cholesterol mass. Annie St-Pierre and colleagues followed 2,072 men in the Quebec Cardiovascular Study for 13 years and found that cholesterol carried in small, dense LDL predicted ischemic heart disease risk, while cholesterol carried in large LDL did not, a pattern consistent with small particles being the more atherogenic fraction independent of total LDL-C.

What Widens the Gap Between LDL-C and LDL-P

Elevated triglycerides

Higher triglycerides shift LDL production toward smaller, cholesterol-poor particles, so more particles are needed to carry the same LDL-C.

Insulin resistance

Insulin resistance raises VLDL output from the liver, and the remodeling that follows tends to favor smaller LDL particles.

Obesity and metabolic syndrome

Both are associated with the same small, dense LDL shift, widening the gap between what LDL-C shows and what LDL-P shows.

Allan Sniderman and colleagues laid this out in a 2019 narrative review in JAMA Cardiology, estimating that ApoB and LDL-C are discordant in roughly 20 to 60 percent of people, with the gap concentrated in exactly the groups above: high triglycerides, obesity, and diabetes. Their conclusion was direct: when the two measures disagree, cardiovascular risk tends to track the particle count, not the cholesterol mass. This is also why a rising insulin resistance pattern is often the earliest clue that LDL-C and LDL-P are about to drift apart, sometimes before either lipid number looks abnormal on its own.

How to read an LDL-P or ApoB result

William Cromwell, James Otvos, and colleagues followed the Framingham Offspring Study cohort and compared how well LDL-P, LDL-C, and non-HDL-C identified genuinely low-risk people. Among people classified as low risk by being below the 25th percentile on each measure, the group defined by low LDL-P had a future cardiovascular event rate of 59 per 1,000 person-years. The group defined by low LDL-C instead had an event rate of 81 per 1,000 person-years, and the group defined by low non-HDL-C had 74 per 1,000 person-years. In other words, a low LDL-C did not identify as clean a low-risk group as a low LDL-P did, because some people with low cholesterol mass still had a high particle count underneath it.

Most NMR labs, including Mayo Clinic Laboratories, report LDL-P against a reference range built on these bands: desirable is below 1,000 nmol/L, above desirable is 1,000 to 1,299, borderline high is 1,300 to 1,599, high is 1,600 to 2,000, and very high is 2,000 nmol/L or above. Ranges and units differ across labs and testing methods, so read your result against the range printed on your own report rather than the numbers above.

LDL-C and LDL-P (or ApoB) agree, both in range

The straightforward case. LDL-C is giving an accurate read on particle burden and does not need a second measure to confirm it.

LDL-C looks fine, LDL-P or ApoB is elevated

The discordant pattern most likely to be missed by a standard panel alone, especially common with high triglycerides, insulin resistance, or a low-carbohydrate diet. Worth tracking the particle number directly rather than assuming the normal LDL-C tells the full story.

LDL-C is elevated, LDL-P or ApoB is also elevated

Concordant elevation. Both measures point the same direction, which is the pattern standard cholesterol guidelines were built around.

The 2018 AHA/ACC Multi-Society Guideline on the Management of Blood Cholesterol lists an ApoB of 130 mg/dL or higher as a risk-enhancing factor that can tip a borderline treatment decision, a reflection of the same particle-count logic behind LDL-P, expressed in a different unit and a different, though closely related, particle pool.

The normal LDL-C misconception

Common misconception

A normal LDL cholesterol is often treated as proof that LDL-related risk is under control. James Otvos, Samia Mora, and colleagues examined discordant cases in the Multi-Ethnic Study of Atherosclerosis and found that when LDL-C and LDL-P disagreed, LDL-P predicted cardiovascular events (hazard ratio 1.45) while LDL-C did not (hazard ratio 1.07, not statistically significant). A normal LDL-C can still sit on top of an elevated particle count.

The same pattern held in a much larger cohort. Samia Mora, Julie Buring, and Paul Ridker followed 27,533 women in the Women's Health Study for a median of 17.2 years and recorded 1,070 incident coronary events. When LDL-C disagreed with ApoB or LDL-P, using LDL-C alone either underestimated or overestimated a woman's actual coronary risk, depending on which direction the discordance ran. The size of that error is exactly why the particle-based measures exist as a check rather than a curiosity.

Worth knowing

This does not mean LDL-C is a poor measurement or that everyone needs an NMR panel. Most people are concordant, meaning LDL-C and LDL-P point the same direction, and LDL-C remains the number that decades of statin trial evidence are built around. LDL-P and ApoB matter most as a targeted check for the specific groups where discordance concentrates: elevated triglycerides, insulin resistance, obesity, and low-carbohydrate dieters.

What to do when your numbers disagree

Practical Steps

1

Check whether you are in a discordance-prone group first

Elevated triglycerides, insulin resistance, obesity, and low-carbohydrate diets are the situations Sniderman and colleagues flagged as carrying the widest LDL-C to particle-count gap. If none apply, LDL-C alone is less likely to be misleading.

2

Ask for LDL-P or ApoB alongside your standard panel

Either one addresses the same discordance problem. ApoB is more widely available on standard lab requisitions; LDL-P specifically requires NMR-based testing. See the Lab Work and Biomarkers Protocol for how to fit this into a broader testing plan.

3

When the two disagree, weight the particle-based number more heavily

The Framingham, MESA, and Women's Health Study data above all point the same direction: in discordant cases, the particle count is the number that kept predicting cardiovascular events.

4

Address what is driving the gap, not just the number

Because the discordance is usually rooted in triglycerides and insulin resistance, interventions that improve those (visceral fat loss, aerobic training, reduced added sugar) tend to narrow the LDL-C to LDL-P gap over time, not just move either number in isolation.

Frequently asked questions

What is the difference between LDL-P and ApoB?

LDL-P counts only LDL particles, measured by NMR spectroscopy. ApoB counts every particle that carries one ApoB protein, which includes LDL, VLDL, and IDL. Because LDL particles make up most of that pool in most people, LDL-P and ApoB usually move together, but ApoB is the broader measure and is more widely available on routine lab orders.

Is LDL-P the same thing as small, dense LDL?

No. LDL-P is a total count of all LDL particles regardless of size. Small, dense LDL is a specific subfraction of that total. St-Pierre and colleagues' Quebec Cardiovascular Study found the small, dense fraction carried most of the cardiovascular risk associated with LDL size, but LDL-P as reported by a standard NMR panel is the sum across all particle sizes, not the small fraction alone.

If I already have ApoB, do I also need LDL-P?

Generally not. ApoB and LDL-P capture largely the same information for most people, since LDL particles dominate the ApoB-carrying pool. Getting both adds little beyond getting one, so most clinicians treat them as interchangeable options rather than complementary tests.

Can my LDL cholesterol really be normal while my particle count is high?

Yes, and the research suggests this is not rare. Otvos, Mora, and colleagues found that among people whose LDL-C and LDL-P disagreed in the Multi-Ethnic Study of Atherosclerosis, LDL-P predicted future cardiovascular events while LDL-C alone did not. The gap is most common with elevated triglycerides, insulin resistance, obesity, or a low-carbohydrate diet.

How often should I retest LDL-P or ApoB?

There is no fixed rule specific to LDL-P, but it follows the same logic as any lipid marker: retest every 6 to 12 months if you are actively changing diet, training, weight, or medication, and roughly annually once your numbers and the gap between LDL-C and LDL-P have stabilized.

What to Remember

  • →LDL-C measures the cholesterol mass inside LDL particles, while LDL-P counts the particles directly, usually by NMR spectroscopy. The two only agree when cholesterol per particle stays roughly constant.
  • →Cromwell, Otvos, and colleagues found that in the Framingham Offspring Study, a low LDL-P identified a genuinely lower-risk group (59 events per 1,000 person-years) than an equivalently low LDL-C did (81 per 1,000 person-years).
  • →Sniderman and colleagues estimated that LDL-C and ApoB (a closely related particle measure) are discordant in roughly 20 to 60 percent of people, concentrated in those with elevated triglycerides, obesity, insulin resistance, or a low-carbohydrate diet.
  • →In the Multi-Ethnic Study of Atherosclerosis, discordant cases showed LDL-P predicting future cardiovascular events (hazard ratio 1.45) while LDL-C alone did not (hazard ratio 1.07, not statistically significant).
  • →Mora, Buring, and Ridker followed 27,533 women for a median of 17.2 years and found that relying on LDL-C alone under- or overestimated coronary risk whenever it disagreed with ApoB or LDL-P.
  • →Most people are concordant, so LDL-P or ApoB is most useful as a targeted check for elevated triglycerides, insulin resistance, obesity, or low-carbohydrate dieting rather than a routine addition for everyone.

Related on Protocol

LearnHealth

How to Interpret Your Lipid Panel: LDL Particles, ApoB, and What Actually Matters

The full standard and advanced lipid panel, including ApoB and Lp(a), and how to read them together.

Read
LearnHealth

What Insulin Resistance Looks Like in Your Wearable Data Before You Know You Have It

Insulin resistance is one of the main drivers that widens the gap between LDL-C and LDL-P, often before either lipid number looks abnormal.

Read
ProtocolHealth

The Lab Work and Biomarkers Protocol

A framework for deciding which labs to track, how often, and how to read a trend rather than a single result.

Read

Track your biomarker trends alongside the rest of your data

Protocol connects lab results like LDL-P and ApoB to your daily wearable data, so you can see which changes actually move the numbers that matter.

Get started free

References

Key Researchers

  • James Otvos (LipoScience / University of North Carolina) Developed NMR-based lipoprotein particle analysis and led much of the foundational research on LDL-C and LDL-P discordance.
  • Allan Sniderman (McGill University) Leading researcher on ApoB and particle-based cardiovascular risk assessment, and lead author of the 2019 JAMA Cardiology narrative review on discordance.
  • Samia Mora (Brigham and Women's Hospital) Co-author of the Women's Health Study analysis quantifying how much LDL-C alone misestimates coronary risk when it disagrees with particle-based measures.

Key Studies

  • Jeyarajah, Cromwell, and Otvos (2006) Clinics in Laboratory Medicine. Described the NMR spectroscopy methodology used to directly count LDL particles by size class.
  • Cromwell, Otvos, Keyes, and colleagues (2007) Journal of Clinical Lipidology. Framingham Offspring Study analysis showing a low LDL-P identified a genuinely lower-risk group than an equivalently low LDL-C or non-HDL-C.
  • St-Pierre, Cantin, Dagenais, and colleagues (2005) Arteriosclerosis, Thrombosis, and Vascular Biology. Quebec Cardiovascular Study, 13-year follow-up, found small dense LDL cholesterol predicted ischemic heart disease risk while large LDL cholesterol did not.
  • Otvos, Mora, Shalaurova, and colleagues (2011) Journal of Clinical Lipidology. Multi-Ethnic Study of Atherosclerosis analysis showing LDL-P predicted cardiovascular events in discordant cases while LDL-C alone did not.
  • Mora, Buring, and Ridker (2014) Circulation. Women's Health Study, 27,533 women, median 17.2-year follow-up, found LDL-C alone under- or overestimated coronary risk when discordant with ApoB or LDL-P.
  • Sniderman, Thanassoulis, Glavinovic, and colleagues (2019) JAMA Cardiology. Narrative review estimating LDL-C and ApoB are discordant in roughly 20 to 60 percent of people, concentrated in those with high triglycerides, obesity, or diabetes.

Guidelines

  • 2018 AHA/ACC Multi-Society Guideline on the Management of Blood Cholesterol Circulation. Lists an ApoB of 130 mg/dL or higher as a risk-enhancing factor for treatment decisions, reflecting the same particle-count logic as LDL-P.
  • Mayo Clinic Laboratories, NMR LipoProfile reference ranges Reports LDL-P against bands of desirable (under 1,000 nmol/L), above desirable, borderline high, high, and very high; ranges vary by lab and method.